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There is signiﬁcant variability in antidepressant treatment outcome, with B30–40% of patients with major depressive disorder
(MDD) not presenting with adequate response even following several trials. To identify potential biomarkers of response, we
investigated peripheral gene expression patterns of response to antidepressant treatment in MDD. We did this using Affymetrix
HG-U133 Plus2 microarrays in blood samples, from untreated individuals with MDD (N¼63) ascertained at a community
outpatient clinic, pre and post 8-week treatment with citalopram, and used a regression model to assess the impact of gene
expression differences on antidepressant response. We carried out technical validation of signiﬁcant probesets by quantitative
reverse transcriptase PCR and conducted central nervous system follow-up of the most signiﬁcant result in post-mortem brain
samples from 15 subjects who died during a current MDD episode and 11 sudden-death controls. A total of 32 probesets were
differentially expressed according to response to citalopram treatment following false discovery rate correction. Interferon
regulatory factor 7 (IRF7) was the most signiﬁcant differentially expressed gene and its expression was upregulated by
citalopramtreatmentinindividualswhorespondedtotreatment.Wefoundtheseresultstobeconcordantwithourobservationof
decreasedexpression ofIRF7 inthe prefrontal cortex of MDDs with negative toxicological evidence for antidepressant treatment
at the time of death. These ﬁndings point to IRF7 as a gene of interest in studies investigating genomic factors associated with
antidepressant response.
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Introduction
Major depressive disorder (MDD) is a debilitating and chronic
condition that affects between 5 and 10% of the general
population.
1 The treatment of MDD includes a variety of
biopsychosocial approaches, but in frontline medical practice,
it is primarily based on pharmacological interventions,
commonly with an initial prescription of a serotonin selective
reuptake inhibitor antidepressant.
2–5 Although antidepres-
sants are generally effective, and in spite of a growing number
of different types and classes, there is signiﬁcant variability in
antidepressanttreatmentoutcome.Almost60%ofpatientsdo
not recover following a single antidepressant trial,
6 and 30 to
40% of patients do not present with an adequate response
following several trials.
2,4,5 The failure to respond has
important individual, economic and social consequences for
both patients and their families.
Although it would be ideal to better target available
treatments to individual patients, we know little about
predictors of response. Among factors associated with
response to antidepressant treatment in MDD, depression
severity, comorbid anxiety disorders, longer duration and
frequency of previous episodes and an older age of onset
have all been identiﬁed as predictors of poor response.
7
However, given low sensitivity and speciﬁcity, none of these
factors are useful when planning treatment options for MDD
patients.
7 Response to pharmacological treatment has also
been demonstrated to segregate in families. Only a handful of
studies, however, have investigated familial patterns of
response to antidepressants,
8–10 and subsequent studies
have investigated the association of genetic variants with
treatment response. As the downstream effects of different
predictors of antidepressant response—be they genetic and/
or environmental—should ultimately be mediated by changes
in gene function, investigating predictors and underlying
biological factors associated with response by means of gene
expression studies may providevaluableinformation andhelp
identify biomarkers of antidepressant response. This
approach has been favorably used in the investigation of
response to treatment for several medical conditions, such
as breast cancer,
11–13 colon cancer
14 and cardiovascular
disease.
15–17
In the context of neuropsychiatric disorders, peripheral
blood gene expression studies of drug response have value
beyond a proxy model of central nervous system (CNS)
phenomena, given that both peripheral and central processes
are involved in the individual response to treatment. Surpris-
ingly, to date, most studies investigating gene expression
changes to antidepressant treatment have been performed in
patients with Alzheimer’s disease,
18–20 whereas most studies
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www.nature.com/tpof antidepressant response in depression have been carried
out in rodent models. There is limited, although promising,
work probing gene expression changes associated with
antidepressant response in patients with MDD.
21–23 Here,
we report on a study assessing changes in genome-wide
expression as a function of 8-week citalopram treatment
response in a sample of patients with current MDD who were
untreatedat the study onset. Toour knowledge, this is the ﬁrst
genome-wide expression study investigating patterns of
response to antidepressant treatment in MDD patients.
Materials and methods
MDD sample. Our subjects were untreated males and
females (N¼63) with a diagnosis of MDD without psychotic
features, according to the SCID-1 (Structured Clinical
Interview for Diagnostic and Statistical Manual of Mental
Disorders-fourth edition (DSM-IV) Axis I Disorders)
ascertained at a community outpatient clinic at the Douglas
Mental Health University Institute (see Supplementary Table 1
for clinical details). Subjects were excluded from the study if
they had comorbidity with other major psychiatric disorders,
including a previous manic or hypomanic episode (diagnosis
of bipolar disorder) or a diagnosis of schizophrenia.
However, subjects were not excluded if they presented with
anxious traits, as anxiety is highly comorbid with MDD. They
were also excluded if they presented comorbidity with
substance disorders or if they had positive tests for illicit
drugs, both pre- and post-citalopram treatment. Subjects
could not have had previously used citalopram and could not
have been treated for the current episode of major
depression if they had a recurrent form of MDD (46.8%
recurrent MDD; Figure 1).
Citalopram treatment. Patients were treated with citalo-
pram for a total of 8 weeks, starting with an initial dose of
10mg per day, which was subsequently titrated up to a
maximum of 60mg per day. Assessments of depression
severity were carried out three times during the trial
(pretreatment, 1 month after and post-treatment commence-
ment) using the 21-item Hamilton Rating Scale for
Depression (HAMD-21).
Blood samples and RNA processing. Blood samples were
collected in six PAXgene blood RNA tubes (PreAnalytix,
Hombrechtikon, Switzerland) and two EDTA vacutainer tubes
(BD, Mississauga, Ontario, Canada) from cases before the
start of the trial and again at trial completion. PAXgene tubes
were frozen using a sequential freezing process. This
involved storing tubes at room temperature for 3h,
transferring to 41C overnight,  201C for 6–8h and then
ﬁnally to  801C. Four tubes were used for RNA extraction
and microarray processing and the remaining two tubes were
kept at  801C for subsequent RNA extraction and
microarray validation studies. The EDTA tubes were used
to obtain plasma for citalopram concentration measures.
All subjects included in the study provided informed consent
and the project was approved by the internal review board
for the Douglas Mental Health University Institute.
TheRNAusedinthisstudyhadaminimumA260/A280ratio
of 41.9. Integrity and possible degradation of the RNA
samples was determined using a 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA, USA) and samples had an
average RNA integrity number of 8.4 and a 28S/18S ratio
of 41.6.
High-performance liquid chromatography. High-performance
liquid chromatography analysis was carried out to determine
subject compliance at the end of the trial. Citalopram
concentrations were determined from plasma removed from
week 8 blood tubes following centrifugation. Plasma samples
were transferred to cryogenic tubes for storage at  801C until
time for use.
For drug extraction, 1ml of plasma was ﬁrst spiked with
150ng desipramine, which acted as an internal standard, and
then basiﬁed with 100ml NaOH. To this, 10ml of 1%
butanol:isoamyl alcohol was added to bring the drug into the
aqueous phase. The drug was then back-extracted using
200ml HCl, and subsequently 50ml was injected into the high-
performance liquid chromatography machine. The samples
were run through a reverse-phase C-18 column and peaks
were detected with an ultraviolet detector. Citalopram
concentration measures were derived using a standard curve
constructed from plasma spiked with known concentrations of
citalopram and processed as mentioned above. To take into
account intraday variability, new standard curves were made
before each high-performance liquid chromatography run.
Microarrays. We used the Affymetrix GeneChip Human
Genome U133 Plus 2.0 array (Affymetrix, Santa Clara, CA,
USA), consisting of 54000 probesets, allowing for the
analysis of 47000 transcripts, representative of 38500
Week 0
Blood draw (PAXgene and EDTA)
Clinical Questionnaires1
HPLC
Gene Expression Array
Clinical Questionnaires2
Side-effects
Blood draw (PAXgene and EDTA)
Clinical Questionnaires3
HPLC
Side-effects
Gene Expression Array
Week 4 Week 8
Figure 1 Timeline and steps taken within the 8-week citalopram trial.
1SCID-I; SCID-II; sociodemographic questionnaire; HAMD-21 and Hamilton Anxiety questionnaire.
2HAMD-21 and Hamilton Anxiety questionnaire.
3HAMD-21 and Hamilton Anxiety questionnaire. Abbreviations: HAMD-21, 21-item Hamilton Rating Scale for Depression;
HPLC, high-performance liquid chromatography; SCID-I, Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-fourth edition (DSM-IV) Axis I
Disorders; SCID-II, Structured Clinical Interview for DSM-IV Axis II Personality Disorders.
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hybridization to the array and normalization were performed
as suggested by the manufacturer and described in the
Affymetrix GeneChip Expression Analysis Manual (Affymetrix).
The GeneChip IVT Express and the GeneChip Hybridization,
Wash and Stain kits from Affymetrix were used for ﬁrst and
second complementary DNA synthesis, IVT/labeling and
puriﬁcation of RNA, fragmentation and puriﬁcation. GeneChip
analysis was performed as described below.
Data analysis. Normalization of gene expression arrays
was executed using Robust Multi-Array as implemented in
Partek Genomics Suite (Partek, St Louis, MO, USA; Version
6.3 (03.10.08)), with initial probeset ﬁltering based on
Microarray Suite 5 (MAS5) present/absent calls, whereby
only those probesets present in at least 75% of the total
sample were retained for further analysis. This ﬁltering
procedure is based on the methods described by
McClintick and Edenberg
24 whereby the use of present-call
ﬁltering functions in minimizing the impact of large differential
signals explained by a small proportion of the sample.
Following this procedure, the number of probesets was
reduced to 19277. We also removed probesets associated
with the Y chromosome to minimize the likelihood of false
positive results arising from the inclusion of probesets from
this chromosome. Several indicators of RNA quality were
used to preﬁlter samples before analysis; these included
b-actin 50/30 ratio (X0.3), glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) 50/30 ratio (X0.5) and RawQ.
Outlier detection for arrays was also carried out using
principal component analysis.
Following initial ﬁltering, the remaining analyses were
carriedoutusingthestatisticalsoftwareR(www.r-project.org).
For the identiﬁcation of the number of probesets to be used
in our analyses to identify a set of differentially expressed
genes according to response to citalopram treatment, we
used a two-step statistical approach. First, we preselected a
set of 1160 genes showing the highest fold change in log2
expression between pre- and post-treatment. In our sample,
this corresponded to a fold change X1.08 or, alternatively,
p0.92. Subsequently, a regression model was carried out
for each gene using the difference between pre- and post-
HAMD-21 scores as the dependent variable and the
difference in log2 expression as the independent variable.
We accounted for the multiplicity of tests by adjusting the
P-values such that the false discovery rate (FDR) was o10%.
Gene expression validation. The GenomeLab GeXP
Genetic Analysis System (Beckman Coulter, Mississauga,
Ontario, Canada) was used to validate signiﬁcant gene
expression ﬁndings. This was carried out through Genome
Quebec at the RNomics Laboratory at the University of
Sherbrooke (Sherbrooke, Quebec, Canada). The GeXP
system enabled the multiplexing of 30 genes within a single
sample well through the use of both gene-speciﬁc and
universal primers for ampliﬁcation of complementary DNA
fragments of varying length. Using capillary electrophoresis,
at the end of the PCR, fragments migrate by size and thus
separate into gene-speciﬁc bands, which can be visualized
as peaks in a chromatogram. The area under the curve is
equivalent to the concentration of mRNA in the original
sample. The concentration measures are scaled to a control
RNA sample, which was included on each plate and then
normalized to GAPDH. The sample used for this consisted of
pre- and post-RNA samples for all subjects included in the
analyses and a control RNA sample from peripheral blood.
Follow-up gene expression studies in the prefrontal
cortex. A TaqMan gene expression assay for interferon
regulatory factor 7 (IRF7) was used to investigate the
expression of this gene in an all-male sample of 15
subjects who died during a depressive episode (average
age¼36.8±11.2 years) and a group of 11 sudden-death,
psychiatrically normal controls (average age¼34.3±11.5
years) in the prefrontal cortex. The groups were similar in
age (P¼0.42), brain pH (P¼0.481) or post-mortem interval
(P¼0.854). Toxicological investigation of post-mortem
tissue showed no evidence of antidepressants or other
psychotropic treatments. RNA was extracted from brain
tissue using the RNeasy Lipid Tissue Kit from Qiagen (Toronto,
Ontario, Canada). RNA concentration was assessed using
a Nanodrop (Thermo Scientiﬁc, Wilmington, DE, USA)
and RNA quality using the 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA), and brain samples
had an average RNA integrity number of 7.2.
Complementary DNA was produced using Moloney murine
leukemia virus reverse-transcriptase and Oligo-dT primers
and subsequently diluted to a concentration of 2.5ngml
–1 for
use in quantitative reverse transcriptase-PCR. Quantitative
reverse transcriptase- was performed in 384-well plates on the
7900HT Real-Time PCR system from Applied Biosystems
(Carlsbad, CA, USA) under fast conditions using PerfeCTa
qPCR Fastmix (Quanta Biosciences, Gaithersburg, MD, USA).
Target and endogenous control (b-actin) were run in the same
well and plates were analyzed using the DCt method in RQ
Manager (Applied Biosystems) with the calibrator being a
sample with low variability between replicates.
Results
A total of 63 subjects with MDD were treated with citalopram
for 8 weeks and their gene expression proﬁles were obtained
pre- and post-treatment. Demographic and baseline clinical
variables had no signiﬁcant effect on treatment outcome
(Supplementary Table 2). We observed no instances of
suicidal behavior or signiﬁcant increase in ideation during the
trial, necessitating trial discontinuation. As well, past suicidal
behavior had no effect on the results observed in the
citalopram sample. Side effects were measured after 4 and
8 weeks of treatment, and there were no signiﬁcant
differences between responders and nonresponders in side-
effect proﬁles at week 4 (P-value¼0.98) or at week 8
(P-value¼0.08). All subjects had detectable levels of serum
citalopram at the end of 8 weeks, and we observed a
signiﬁcant correlation between citalopram dose and plasma
concentration (r¼0.392, P-value¼0.002).
Differential gene expression according to treatment
irrespective of treatment response. At the outset,
probesets were ﬁltered based on their presence in 75% of
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of probesets to 19277. The ﬁrst step in our analyses was to
select a subset of probesets showing change in expression
according to treatment irrespective of response. Three
criteria were used for this purpose: (1) signiﬁcance, (2) fold
change and (3) effect size. The lists of probesets pertaining
to each criterion are summarized in Supplementary Tables
3–5. The Venn diagram (Supplementary Figure 1) illustrates
the number of probesets unique and common to each of the
aforementioned criteria. The 417 common probesets were
then used in the analysis of treatment response, as outlined
below.
Gene expression changes associated with response to
antidepressant treatment. For the assessment of
response, we did not utilize the more traditional procedure of
dichotomization of subjects into responder and nonresponder
groups based on a HAMD cutoff, but opted instead to analyze
response quantitatively. This is because of HAMD scores
being continuous measures and the fact that depressive/
response states are not necessarily categorical following 8
weeks of treatment. Furthermore, from a statistical point of
view, dichotomization of continuous variables is not
recommended as it can result in an unnecessary loss of
information, as well as lead to reduced statistical power and an
increased probability of type II error.
25
In order to determine gene expression changes associated
with treatment response, we conducted regression analyses
using the log fold change of the 417 differentially expressed
probesets, which are differentially expressed according to
treatment, to predict the change in HAMD scores between pre
and post-treatment. We found that changes in the expression
of 69 probesets signiﬁcantly predicted the change in HAMD
scores following treatment (P-value o0.05). Of these, 32
probesets remained statistically signiﬁcant after FDR correc-
tion (FDR p0.10; Table 1). Using DAVID
26 to probe over-
representedontologies,theseprobesetswerefoundtocodefor
genes involved in immune response, transcription factors,
apoptosisandothercellularprocesses(Table2).Amongthe32
probesets, probeset 208436_s_at, which maps to the gene
coding for IRF7, a transcription factor regulating the cytokine
interferon-a, was the only one that was signiﬁcantly associated
with the change in depression severity using an FDR of 0.05.
Technical validation of microarray ﬁndings. The
validation results are shown in Table 3. Expression values
in the validation assays were consistent and in the same
direction with those observed in the array; however, only
eight of these genes displayed signiﬁcant correlations. IRF7
expression values observed using these techniques were
similar to those seen using the microarrays. To exclude the
possibility that the differences observed in IRF7 were
because of inﬂammatory processes associated with
possible infections, we investigated whether they were
associated with changes in white cell counts. However, no
signiﬁcant differences were observed between pre- and post-
treatment measures (P¼0.12).
Expression of IRF7 in prefrontal cortex. To gain insight
into the possible CNS validity of our peripheral results, we
investigated IRF7 expression in prefrontal cortex, a brain
region thought to play an important role in the neurobiology of
major depression.
27 To this end, we studied the levels of
IRF7 by means of quantitative reverse transcriptase-PCR
using a TaqMan assay in 15 subjects who died in the context
of an episode of MDD and 11 sudden-death controls with
comparable age, post-mortem interval, RNA integrity number
and pH, and no current or lifetime history of MDD. We
found that IRF7 was signiﬁcantly downregulated in MDD
subjects when compared with controls (fold change¼ 1.74,
P-value¼0.01).
Discussion
A large proportion of patients taking antidepressants display
unfavorableorminimalresponseand,asaconsequence,they
typically are exposed to multiple antidepressant trials and
endure a protracted illness course. The potential individual
and societal advantages resulting from the effective identiﬁ-
cation of biomarkers of antidepressant response are numer-
ous and ranging from economic beneﬁts to reduced medical
and social burden. In this study we carried out an analysis of
peripheral gene expression with the aim of determining
potential biomarkers for response to citalopram. We have
identiﬁed a set of 32 probesets whose differential expression
is signiﬁcantly associated with the change observed in
depression severity following treatment. As well, we have
foundadditionalevidencefortheroleofimmunedysregulation
in both the periphery and the brain.
IRF7 is part of a nine-member transcription factor family
responsible for the transcriptional regulation of interferon-
mediated signaling pathways.
28 IRF7 has been shown to
complex with IRF1, IRF3 and histone transacetylases to
regulate transcription of the proinﬂammatory cytokine, inter-
feron-a. In our study, we observed an upregulation of IRF7
following treatment with citalopram. IRF7 upregulation could
betheresultofcitalopramstimulatingﬂuctuationsininterferon
levels,
29 or through IRF7 promoter methylation.
30 Initiation of
the inﬂammatory immune response gives rise to changes in
neuromodulatory effects mimicking the outcomes elicited by
stressful life events.
31 The effects of immune-derived stress
on the CNS and the periphery, and the subsequent effects on
depressed and anxious mood, are not a point of contention in
MDD research;
32–34 however, the exact mechanistic nature of
this process and the speciﬁc effects of immunological agents
are not completely elucidated. In psychiatric disorders, with
particular emphasis on depression, there is evidence for a
dysregulation of the balance of immunomodulatory cytokines
in consequence to an increased preponderance of proin-
ﬂammatorycytokines(forexample,interleukin-1b,interleukin-6,
tumor necrosis factor-a and interferon-a-a) due to stress.
35–38
As well, the administration of pro-inﬂammatory cytokines in
both animals
39 and euthymic subjects
40,41 triggers the onset
of depressive symptomatology, such as depressed mood,
fatigue, anhedonia and anorexia.
42–44 Furthermore, altera-
tions in the proinﬂammatory/anti-inﬂammatory cytokine bal-
ance has been demonstrated as being an explanatory factor
for the way the brain adapts to stress.
45 The administration of
interferon-a has been demonstrated to generate depressive-
like symptoms,
46,47 although its exact mechanism of action
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underexplored.
48
Recently, Spijker et al.
49 published peripheral gene
expression ﬁndings following stimulation with lipopolysac-
charide, a lipoglycan shown to produce depressive-like
behaviors in humans.
50 In this study, the authors found a
difference in stimulated gene expression in MDD versus
controls, leading to the identiﬁcation of a predominantly
immune-related biomarker with enough sensitivity and speci-
ﬁcity to differentiate between cases and controls.
Traditionally, studies have used peripheral cells, such as
lymphocytes or platelets, from affected patients to investigate
markers of illness in vitro. These studies have several
limitations. For instance, cell models, although informative,
do not represent normal cell environment and lack the
complexity of the host organism. The investigation of
peripheral cells in vivo, rather than in vitro, addresses some
of the limitations of previous studies, and as such, a few gene
expression studies investigating peripheral samples have
been recently conducted in neuropsychiatric conditions
such as autism,
51–55 schizophrenia
56,57 and Alzheimer’s
disease.
19,20 However, one of the central questions of these
studies, particularly when they are interested in the investiga-
tion of markers of illness, is whether or not their ﬁndings are
representative of gene changes taking place in the brain.
Peripheral studies of drug response, on the other hand, have
valuenotonlyasaproxymodelofCNSphenomena,butasan
indicator of peripheral processes involved in individual
response to treatment.
58–62 Examples of peripheral factors
involved in drug response include pharmacokinetic, pharma-
codynamic, metabolizing and endocrinal factors, all of which
may inﬂuence peripheral mRNA expression.
That said, it remains important to assess the CNS validity of
mRNA expression differences seen in peripheral tissues.
Table 1 The 32 probesets found to be signiﬁcantly associated with the change in HAMD score and meeting 0.10 FDR criteria
Probeset Gene
symbol
Gene title Cytoband P-value
(uncorrected)
FDR Fold
change
Direction
208436_s_at IRF7 Interferon regulatory factor 7 11p15.5 0.0002 0.0316 1.12 UP
228230_at PRIC285 Peroxisomal proliferator-activated
receptor A interacting complex 285
20q13.33 0.0021 0.0644 1.10 UP
218429_s_at C19orf66 Chromosome 19 open reading frame 66 19p13.2 0.0024 0.0653 1.11 UP
209417_s_at IFI35 Interferon-induced protein 35 17q21 0.0025 0.0656 1.10 UP
239266_at —— — 0.0027 0.0660  1.07 DOWN
53720_at C19orf66 Chromosome 19 open reading frame 66 19p13.2 0.0037 0.0676 1.11 UP
203258_at DRAP1 DR1-associated protein 1 (negative
cofactor 2 a)
11q13.3 0.004 0.0680 1.09 UP
212647_at RRAS Related RAS viral (r-ras) oncogene
homolog
19q13.3-qter 0.004 0.0680 1.11 UP
229803_s_at —— — 0.0042 0.0682  1.08 DOWN
227299_at CCNI Cyclin I 4q21.1 0.0044 0.0684 1.10 UP
210740_s_at ITPK1 Inositol 1,3,4-triphosphate 5/6 kinase 14q31 0.005 0.0688 1.08 UP
206284_x_at CLTB Clathrin, light chain (Lcb) 4q2-q3|5q35 0.0054 0.0691 1.11 UP
1555491_a_at C19orf66 Chromosome 19 open reading frame 66 19p13.2 0.0057 0.0692 1.09 UP
229350_x_at PARP10 Poly (ADP-ribose) polymerase family,
member 10
8q24.3 0.0066 0.0735 1.08 UP
215749_s_at GORASP1 Golgi reassembly stacking protein 1,
65kDa
3p22-p21.33 0.0078 0.0781 1.08 UP
205875_s_at TREX1 Three prime repair exonuclease 1 3p21.31 0.0097 0.0838 1.10 UP
1562836_at —— — 0.0109 0.0867  1.12 DOWN
1558937_s_at —— — 0.0122 0.0893  1.13 DOWN
202779_s_at UBE2S Similar to ubiquitin-conjugating
enzyme E2
Subiquitin-conjugating enzyme E2S
19q13.43 0.0128 0.0904 1.13 UP
225058_at GPR108 G protein-coupled receptor 108 19p13.3 0.0132 0.0911 1.10 UP
220998_s_at UNC93B1 Unc-93 homolog B1 (C. elegans) 11q13 0.0147 0.0933 1.09 UP
235292_at FLJ32255 Hypothetical protein LOC643977 5p12 0.0148 0.0935 1.10 UP
202687_s_at TNFSF10 Tumor necrosis factor (ligand)
superfamily, member 10
3q26 0.0157 0.0947 1.13 UP
207713_s_at RBCK1 RanBP-type and C3HC4-type zinc
ﬁnger containing 1
20p13 0.0164 0.0955 1.09 UP
223152_at PPP1R12C Protein phosphatase 1, regulatory
(inhibitor) subunit 12C
19q13.42 0.0169 0.0961 1.12 UP
211250_s_at SH3BP2 SH3-domain binding protein 2 4p16.3 0.0172 0.0964 1.09 UP
213621_s_at GUK1 Guanylate kinase 1 1q32-q41 0.0178 0.0971 1.15 UP
218961_s_at PNKP Polynucleotide kinase 30-phosphatase 19q13.3-q13.4 0.0187 0.0980 1.08 UP
212983_at HRAS v-Ha-ras Harvey rat sarcoma viral
oncogene homolog
11p15.5 0.0193 0.0985 1.12 UP
222660_s_at RNF38 Ring ﬁnger protein 38 9p13 0.0197 0.0989  1.08 DOWN
225294_s_at TRAPPC1 Trafﬁcking protein particle complex 1 17p13.1 0.0202 0.0993 1.11 UP
204858_s_at TYMP Thymidine phosphorylase 22q13|22q13.33 0.0207 0.0997 1.13 UP
Abbreviations: DOWN, downregulated; FDR, false discovery rate; HAMD, Hamilton Rating Scale for Depression; UP, upregulated.
Informationofdifferentialgeneexpressionbetweenpre-andpost-treatmentvaluesisrepresentedthroughafoldchange(post/pre)andthedirectionalityofexpression
following treatment (UP and DOWN).
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expression of IRF7, we found its expression to be signiﬁcantly
downregulated in MDD compared with controls in frontal
cortex. A limitation of post-mortem investigations is that
information on antidepressant medication history of individual
subjects is restricted. However, availability of toxicological
data partially reduces the impact of this limitation. Although
our post-mortem results do not represent by themselves a
validation of our peripheral ﬁndings, they certainly support the
hypothesis that IRF7 may play a role in brain processes
associated with depression. We are limited in our design by
the lack of a placebo or control group for comparison.
However, it must be said that the aim of the present study
was to determine biomarkers of response and not to perform
an assessment of drug efﬁcacy. Although assessing mole-
cular processes associated with placebo effects is also a
relevant question, withholding potentially beneﬁcial treatment
from actively depressed individuals is nowadays considered
unethical in many countries, including the one where this
study was conducted. It was nevertheless reassuring that we
observed similarities with other studies having used citalo-
pram regarding noticeable side effects during the course of
treatment
63 and in the range of citalopram concentrations
quantiﬁed in plasma.
64–67 In all, our ﬁndings do provide good
indications of plausible treatment targets and likely biomar-
kers for depression and citalopram response.
Table 2 Gene ontology analysis of probesets signiﬁcantly associated with citalopram response
Category Term Count % P-value
Biological process Nucleobase, nucleoside and nucleotide metabolic process 4 13.33% 0.0057
Molecular function Hydrolase activity, acting on acid anhydrides 5 16.67% 0.0109
Molecular function Hydrolase activity, acting on acid anhydrides,
in phosphorus-containing anhydrides
5 16.67% 0.0133
Molecular function Pyrophosphatase activity 5 16.67% 0.0146
Molecular function Nuclease activity 3 10.00% 0.0278
Cellular component Golgi apparatus 4 13.33% 0.0302
Molecular function Ribonucleotide binding 7 23.33% 0.0341
Cellular component Golgi apparatus 4 13.33% 0.0399
Molecular function Purine nucleotide binding 7 23.33% 0.0409
Biological process Nucleotide metabolic process 3 10.00% 0.0434
Molecular function Purine ribonucleotide binding 7 23.33% 0.0460
Biological process DNA replication 3 10.00% 0.0474
Count refers to the number of probesets (out of 32) that belong to the ontological category and term, the percentage (%) to which this corresponds and the P-value of
the association.
Table 3 Validation of microarray ﬁndings using GeXP or qPCR
Gene Probeset Uncorrected
P-value
FDR Fold change
(pre/post)
Fold change
(pre/post)
Pearson’s correlation
Microarray GeXP or real time rP -value
IRF7 208436_s_at 0.0002 0.032 1.12 1.09 0.631 o0.0001
PRIC285 228230_at 0.002 0.064 1.10 1.15  0.115 0.234
C19orf66 218429_s_at 0.002 0.065 1.11 1.17 0.286 0.003
IFI35 209417_s_at 0.003 0.066 1.10 1.03 0.477 o0.0001
C19orf66 53720_at 0.004 0.068 1.11 1.17 0.248 0.01
CCN1 227299_at 0.004 0.068 1.10 1.06  0.063 0.255
DRAP1 203258_at 0.004 0.068 1.09 1.06 0.141 0.066
CLTB 206284_x_at 0.005 0.069 1.11 1.02 0.009 0.461
ITPK1 210740_s_at 0.005 0.069 1.08 1.06 0.036 0.352
C19orf66 1555491_a_at 0.006 0.069 1.09 1.17 0.265 0.006
TREX1 205875_s_at 0.009 0.084 1.10 1.09 0.281 0.001
GPR108 225058_at 0.013 0.091 1.10 1.02  0.076 0.208
FLJ32255 235292_at 0.015 0.093 1.10 1.00 0.085 0.184
UNC93B1 220998_s_at 0.015 0.093 1.09 1.10 0.157 0.046
TNFSF10 202687_s_at 0.016 0.095 1.13 1.03 0.056 0.276
PPP1R12C 223152_at 0.017 0.096 1.12 1.02  0.017 0.428
SH3BP2 211250_s_at 0.017 0.096 1.09 1.01  0.015 0.438
GUK1 213621_s_at 0.018 0.097 1.15 1.12 0.332 o0.0001
HRAS 212983_at 0.019 0.099 1.12 1.07 0.072 0.225
RNF38 222660_s_at 0.019 0.099  1.08 1.01 0.116 0.108
TRAPPC1 225294_s_at 0.02 0.099 1.11 1.03  0.101 0.141
Abbreviations: CCN1, cyclin 1; CLTB, clathrin, light chain (Lcb); C19orf66, chromosome 19 open reading frame 66; DRAP1, DR1-associated protein 1 (negative
cofactor 2 a); FDR, false discovery rate; FLJ32255, hypothetical protein LOC643977; GUK1, guanylate kinase 1; GPR108, G protein-coupled receptor 108; HRAS,
v-Ha-ras Harveyratsarcoma viral oncogene homolog;IFI35,interferon-induced protein 35;IRF7,interferonregulatory factor 7;ITPK1,inositol 1,3,4-triphosphate 5/6
kinase; PARP10, poly (ADP-ribose) polymerase family, member 10; PPP1R12C, protein phosphatase 1, regulatory (inhibitor) subunit 12C; PRIC285, peroxisomal
proliferator-activated receptor A interacting complex 285; RNF38, ring ﬁnger protein 38; SH3BP2, SH3-domain binding protein 2; TNFSF10, tumor necrosis factor
(ligand) superfamily, member 10; TRAPPC1, trafﬁcking protein particle complex 1; TREX1, three prime repair exonuclease 1; UNC93B1, Unc-93 homolog B1
(C. elegans).
Theﬁrstthreecolumnscontaindatafromthemicroarray,whereasthefourthcolumnpresentsfoldchangeresultsfromquantitativevalidationandthelasttwocolumns
give Pearson’s correlation (r) and P-value of the correlation between the microarray results and quantitative validation.
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